REDEFINE 2 (Type 2 Diabetes) In patients with T2D, CagriSema produced significant weight loss alongside glycemic improvements (HbA1c reduction), outperforming the individual components (Lingvay et al., 2025)
Also, as at the moment of writing, no randomized controlled trials (RCTs) have been conducted to specifically assess whether attenuating intestinal inflammation or barrier dysfunction improves cognitive outcomes in post-IIRI settings or related clinical conditions
Appreciation of these issues will determine whether the results of an experiment are relevant for understanding mechanisms of cell death and identification of novel therapeutic targets for most patients or if they are clinically irrelevant and just adding background noise to the literature
[DOI] [PubMed] [Google Scholar] Howard M, Fischer H, Roux J, Santos BC, Gullans SR, Yancey PH, Welch WJ
PMID: 32257855